URL: http://dx.doi.org/10.31703/gpsr.2023(VIII-I).08 DOI: 10.31703/gpsr.2023(VIII-I).08

Citation: Ayesha, Shafi, S., Fatima, N., Ali, M. Z., Zeb, S., & Basheer, I. (2023). Assessing Infection Patterns, Resistant Pathogens and Targeted Bacterial Mechanisms: A Comparative Analysis of Antimicrobial Resistance in Five Countries. *Global Pharmaceutical Sciences Review, VIII*(I), 47-59. https://doi.org/10.31703/gpsr.2023(VIII-I).08

Cite Us

Vol. VIII, No. I (Winter 2023) Pages: 47 – 59 ISSN (Print): 2788-5569 ISSN (Online): 2788-5445

Assessing Infection Patterns, Resistant Pathogens and Targeted Bacterial Mechanisms: A Comparative Analysis of Antimicrobial Resistance in Five Countries

Ayesha [a] Saba Shafi [b] Noor Fatima [c]

Muhammad Zahid Ali [d] Shah Zeb [e] Irum Basheer [f]

Abstract: *Antimicrobial resistance in five countries including USA, India, China, UK, and Pakistan. The analysis reveals high and very high levels of AMR in these countries, with respiratory, urinary tract, bloodstream, and surgical site infections being the most common. The identified resistant pathogens include E. coli, K. pneumonia, P. aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae. Carbapenems, fluoroquinolones, and cephalosporins are commonly used antibiotics, but resistance mechanisms such as enzyme production and altered target sites contribute to the problem. The estimated annual costs associated with AMR are substantial, with the USA spending $35 billion, India $2.5 billion, China $12 billion, UK £1.2 billion, and Pakistan PKR 361.9 million. Various reporting agencies, including the CDC, WHO, and national health organizations, monitor and report on AMR. The abstract also highlights resistance mechanisms such as extended-spectrum beta-lactamase (ESBL), methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistance (MDR), and carbapenem-resistant Enterobacteriaceae (CRE), along with their respective costs. Our findings underscore the urgent need for global collaboration to address AMR effectively. Strategies must be improved surveillance systems, liable antibiotic use, and the development of new antimicrobial agents are decisive to combat the growing threat of AMR and preserve the effectiveness of existing antibiotics.*

Key Words: Antimicrobial Resistance, Comparative Analysis, Bacterial Infections, Antibiotic Resistance Mechanisms of MDR, ESBL

Introduction

When microorganisms like bacteria, viruses, fungi, and parasites develop resistance to antimicrobial agents, this is known as antimicrobial resistance (AMR). (Marston, Dixon, Knisely, Palmore, & Fauci, 2016). Some of these include improper or excessive antibiotic usage, inadequate infection management, and dirty conditions of residence (Acar & Rostel, 2001). Because AMR makes it more difficult to treat infections, it is becoming a major public health issue that is driving up healthcare costs and threatening patient safety. (Hofer, 2019).

The goal of this study was to find better ways to prevent and control infections, encourage the

[a] Department of Allied Health Sciences, Superior University, Lahore, Punjab, Pakistan.
[b] Key Laboratory of Saline–alkali Vegetation Ecology Restoration, Ministry of Education, College of Life Sciences, Northeast Forestry University, Harbin, China.
[c] Institute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Punjab, Pakistan.
[d] Department of Microbiology, Yahya Welfare Complex Hospital, Haripur, KP, Pakistan.
[e] Department of Microbiology and Infection Prevention and Control, Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan.
[f] Key Laboratory of Saline–alkali Vegetation Ecology Restoration, Ministry of Education, College of Life Sciences, Northeast Forestry University, Harbin, China.

Corresponding Author: Irum Basheer (Key Laboratory of Saline–alkali Vegetation Ecology Restoration, Ministry of Education, College of Life Sciences, Northeast Forestry University, Harbin, China.
Email: Irumbashir598@gmail.com)

responsible use of antimicrobials, identify and test novel antimicrobial agents, and better track and report patterns of resistance.

To Understand the Impact of AMR on Public Health

Most at risk are elder people, young children, and individuals with compromised immune systems, all of whom can be adversely affected by antimicrobial resistance pathogens and suffer more morbidity and death as a result (Okeke et al., 2005). Multidrug-resistant bacterial infections, such as those caused by MRSA, can be more challenging to treat, requiring longer hospital stays, more intense care, and potentially more expensive therapies, as discussed by Holmes et al. This may place an undue strain on the healthcare system and lead to higher healthcare costs. Healthcare expenditures and mortality rates aren't the only things affected by antimicrobial resistance. The social and economic repercussions may be far-reaching. Reduced production due to increased morbidity and the loss of a productive workforce due to disease and death are two examples. Antimicrobial resistance (AMR) has repercussions outside the medical and scientific communities; for example, the overuse of antibiotics in cattle production has been linked to the emergence of AMR (Mehdi et al., 2023), (Holmes et al., 2016).

Table 1

Effective Strategies for the Prevention and Control of Antimicrobial Resistance

Effective Strategies	Examples	Prevention and Control of AMR	Protecting Healthcare	Sustainability of Healthcare Systems	AMR Agents	References
Improving infection prevention and control measures	Hand hygiene, isolation precautions, sterilization and disinfection, and antimicrobial stewardship programs	Identifying patients colonized with multidrug-resistant organisms, implementing contact precautions, and promoting vaccination programs	Providing personal protective equipment, training on infection prevention and control, and promoting the well-being of healthcare workers	Addressing healthcare disparities, ensuring healthcare financing, and investing in healthcare infrastructure and workforce development	Bacteria, viruses, fungi, and parasites that develop resistance to antimicrobial drugs	(Tacconelli et al., 2018), (Dai, Sahin, Grover, & Zhang, 2020), (Uchil, Kohli, KateKhaye, Swami, & JCDR, 2014)
Promoting the appropriate use of antimicrobial drugs	Prescribing antibiotics only when necessary, using the most effective antibiotic, and completing the full course of treatment	Implementing antimicrobial stewardship programs, promoting the use of rapid diagnostic tests, and monitoring antimicrobial use and resistance patterns	Ensuring the availability of effective antimicrobial drugs and appropriate use of antibiotics	Promoting healthcare financing, investing in healthcare infrastructure and workforce development, and promoting sustainable healthcare practices	Antibiotic-resistant bacteria, such as *Methicillin-resistant Staphylococcus aureus* (MRSA) and *Vancomycin-resistant Enterococci* (VRE)	
Developing new antimicrobial agents	Research and development of new	Promoting research and development of new	Ensuring the availability of effective	Addressing healthcare disparities, ensuring	Promoting healthcare financing, investing in	

Effective Strategies	Examples	Prevention and Control of AMR	Protecting Healthcare	Sustainability of Healthcare Systems	AMR Agents	References
	antibiotics, vaccines, and alternative therapies	antimicrobial agents, vaccines, and alternative therapies	antimicrobial drugs and appropriate use of antibiotics	healthcare financing, and investing in healthcare infrastructure and workforce development	healthcare infrastructure and workforce development, and promoting sustainable healthcare practices	

Factors that are making the Rate of AMR go up

Overuse and misuse of antibiotics, inadequate infection prevention and control methods, a dearth of novel antibiotics, international trade and travel, antibiotic use in agriculture, and subpar sanitation and hygiene all contribute to the alarming rise in antimicrobial resistance (AMR). These conditions promote the growth and dissemination of antibiotic-resistant bacteria, which in turn makes it more difficult to contain and treat infectious diseases. To restrict the spread of AMR and protect the efficacy of antibiotics, strong measures of prevention and control are required (Laxminarayan et al., 2013).

Antimicrobial medications, such as antibiotics, can be overused and misused, which can lead to resistance in human and animal populations. Frequent use of antimicrobials can foster the development of bacteria that is resistant to the drugs. In recent years, progress in creating new antimicrobial medications has halted. This reduces the number of potential treatments for infections caused by antibiotic-resistant bacteria. The rapid and widespread growth of resistant germs across the world is facilitated by international travel and trade. Poor hand hygiene and other inadequate infection control procedures can facilitate the spread of antibiotic-resistant bacteria in healthcare facilities. When people don't have access to clean water and sanitation, infectious diseases proliferate and more people need to take antimicrobials, which can lead to resistance. The raising of animals with the aid of antimicrobial medications can promote the evolution of drug-resistant microorganisms. Reducing the spread of AMR and protecting the use of antimicrobial medicines both require attention to these variables. This calls for a concerted effort on the part of healthcare professionals, government officials, and the general public (Laxminarayan et al., 2013).

Table 2

Burden of Antimicrobial Resistance (AMR), bacterial Infections and Associated Costs in Selected Countries

Countries	Number of AMR Infections	Most Common Infections	Antibiotics Used	Most Common Resistant Pathogens	Cost of AMR	Reporting Agency	Source
USA	High	Respiratory, Urinary tract, Bloodstream, Surgical site	Carbapenems, fluoroquinolones, cephalosporins	*E. coli*, K. pneumoniae, P. aeruginosa	$35 billion per year	CDC	(Organization, 2002), (Johnson, Hayes, Brown, Hoo, & Ethier, 2014; Organization, 2008), (Zeb, 2019).
India	Very High	Respiratory, Urinary tract, Bloodstream, Surgical site	Carbapenems, fluoroquinolones, cephalosporins	*Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae*	$2.5 billion per year	National Center for Disease Control (NCDC)	
China	Very High	Respiratory, Urinary tract, Bloodstream, Surgical site	Carbapenems, fluoroquinolones, cephalosporins	*E. coli, K. pneumoniae, P. aeruginosa*	$12 billion per year	Chinese Center for Disease Control and Prevention (CCDC)	

Countries	Number of AMR Infections	Most Common Infections	Antibiotics Used	Most Common Resistant Pathogens	Cost of AMR	Reporting Agency	Source
UK	High	Respiratory, Urinary tract, Bloodstream, Surgical site	Carbapenems, fluoroquinolones, cephalosporins	*E. coli, K. pneumoniae, P. aeruginosa*	£1.2 billion per year	Public Health England (PHE)	
Pakistan	High	Respiratory, Urinary tract, Bloodstream, Surgical site	Carbapenems, fluoroquinolones, cephalosporins	*Acinetobacter baumannii, E. coli, K. pneumoniae*	PKR 361.9 million	National Institute of Health (NIH)	

Identify the Current Status of AMR, Including Prevalence and Trends in Bacterial Resistance Patterns & Mechanisms

Mechanism of Resistance Developed by *Extended-spectrum Beta-lactamase*

Bacteria that create *extended-spectrum beta-lactamase (ESBL)* enzymes are resistant to multiple classes of beta-lactam antibiotics. (Coque, Baquero, & Cantón, 2008). Melzer and colleagues studied the Penicillin-binding proteins (PBPs) were the enzymes involved in bacterial cell wall construction, and beta-lactam antibiotics function by binding to and blocking the activity of these enzymes. As a result, bacterial cell wall production was disrupted, and the bacteria decrease. The beta-lactam ring in these antibiotics was hydrolyzed by enzymes produced by ESBL-producing bacteria leaving them ineffective. Beta-lactamases of which ESBLs were also a subset and categorized according to their substrate selectivity and mechanisms of resistance. Unlike other beta-lactamases like penicillinases and cephalosporinases, *extended-spectrum beta-lactamases* (ESBLs) are capable of hydrolyzing a wider variety of beta-lactam antibiotics (Melzer & Petersen, 2007).

The acquisition of plasmids which are mobile replicating genetic components that may be transmitted between bacteria is commonly linked to the evolution of ESBL-mediated resistance. Bacteria that make ESBLs have acquired the ability to produce these enzymes and acquire resistance to beta-lactam antibiotics by acquiring plasmids encoding the genes that code for ESBLs. Alterations to the bacterial cell wall or the presence of efflux pumps, both of which can remove antibiotics from the bacterial cell, are two additional resistance mechanisms that may be present in ESBL-producing bacteria (Khanfar, Bindayna, Senok, & Botta, 2009; Zeb et al., 2022). Infections produced by ESBL-producing bacteria can be particularly challenging to treat because of these resistance mechanisms. ESBL-mediated resistance poses a significant threat to public health because it reduces the efficacy of antibiotics and raises the risk of life-threatening infections. Antimicrobial stewardship programs, infection prevention and control measures, and the prudent use of antibiotics are all examples of prevention tactics that can help lower the number of ESBL-producing bacteria and other multidrug-resistant germs in a given environment (Andes, Craig, & Infection, 2005), (Ahmed et al., 2022).

Mechanism of Resistance Developed by *Methicillin-resistant Staphylococcus Aureus*

Methicillin (a beta-lactam antibiotic) is still effective against MRSA, the bacteria have developed resistance to a number of other medications. Methicillin-resistant *Staphylococcus aureus* is dependent on a movable genetic element that is referred to as the *staphylococcal* cassette chromosome mec (SCCmec). A penicillin-binding protein (PBP2a) with a lower affinity for beta-lactam medicines is encoded by the mecA gene in SCCmec. PBP2a is unaffected by the presence of beta-lactamase-producing microbes, hence MRSA can continue to resist these antibiotics. (Stefani et al., 2012). In addition to the mecA gene, which renders many antibiotics ineffective against MRSA infections, SCCmec has other genes that confer resistance to a wide range of antibiotics, including aminoglycosides and macrolides. In addition to modifying its PBPs, MRSA could develop resistance by producing efflux pumps, which can expel drugs from the bacterial cell, or by altering the bacterial cell wall. Transduction, conjugation, and transformation are all examples of horizontal gene transfer that *S. aureus* can adopt to acquire and spread SCCmec. This has the potential to hasten the spread of MRSA in both clinical and community settings (Algammal et al., 2020).

Multi-drug Resistance (MDR) patterns used by Bacteria

Multidrug-resistant (MDR) bacteria are those that are resistant to multiple classes of antibiotics, which makes them difficult to treat and often results in longer hospital stays, higher healthcare costs, and increased mortality rates (Jubair et al., 2021). Multidrug-resistant (MDR) bacteria's mechanisms of resistance vary per organism and antibiotic, but numerous overarching pathways contribute to MDR overall: Antibiotics are rendered useless by many bacteria due to their efflux pumps, which actively pump antibiotics out of the bacterial cell. It's possible that multidrug-resistant bacteria over-express these pumps, giving them an advantage in clearing the body of medications. Antibiotic resistance is often the result of alterations made by bacteria to the target site of the antibiotic, such as PBPs or ribosomes, which prevents the antibiotic from binding properly. This can be accomplished through horizontal gene transfer or through mutations in the bacterial DNA. Some bacteria develop enzymes, such as beta-lactamases, that can deactivate antibiotics, making them useless. Multidrug-resistant bacteria (MDR bacteria) may develop several distinct enzymes, each of which can neutralize a different group of antibiotics. Bacteria can become resistant to antibiotics by modifying their cell membranes or cell walls to make them impermeable to the drugs. The permeability of the bacterial cell can be changed through mutations or the acquisition of new genes. Multiple drug resistance bacteria (MDR) are resistant to many different antibiotics because they exploit a combination of resistance mechanisms. The selective pressure for the formation and spread of resistant types of bacteria is typically linked to the overuse and misuse of antibiotics. The development of novel medicines and alternative treatment options, together with proper antibiotic use, infection prevention and control measures, and other measures, are all necessary to stop the rise of multidrug-resistant bacteria (Otsuka & Bulletin, 2020), (Yuan et al., 2021), (Boyanova, Markovska, & Mitov, 2019).

Mechanism of resistance developed by *Carbapenem-resistant Enterobacteriaceae*

Carbapenem-resistant Gram-negative bacteria belonging to the family *Enterobacteriaceae* have become resistant to carbapenem medicines, which are typically reserved for the treatment of life-threatening diseases (Tilahun, Kassa, Gedefie, Ashagire, & Resistance, 2021). CRE has developed several resistance mechanisms, including Carbapenemases are enzymes that may degrade the carbapenem antibiotics, rendering them useless. These enzymes are frequently found on plasmids, which are movable genetic elements and can help the spread of CRE by allowing them to move easily between bacteria (Suay-García & Pérez-Gracia, 2019). To prevent carbapenem drugs from penetrating the bacterial cell wall and reaching their target site, certain CRE may have undergone modifications to their outer membrane, rendering them impermeable. Similar to multidrug-resistant bacteria, carbapenem medicines may not be as effective against some CRE because they overexpress efflux pumps that actively remove the drugs from the bacterial cell. Some *carbapenem-resistant enterobacteria* (CRE) may acquire mutations in the target sites of carbapenem antibiotics, such as PBPs or porins that render the antibiotics ineffective. Similar to multidrug-resistant bacteria, CRE may be resistant to various antibiotic classes due to a combination of resistance mechanisms. Overuse and improper use of antibiotics, especially carbapenems, can result in the selection and dissemination of resistant bacteria, which can contribute to the development of CRE. The spread of CRE can be stopped through a combination of infection prevention and control strategies, responsible use of antibiotics, and the discovery of novel drugs (Han et al., 2020), (Ding et al., 2019).

Table 3

Overview of Mode of Action, Bacteria Types, Antibiotic Groups, Resistance Mechanisms, and Worldwide Costs for Four Common Types of Antibiotic Resistance

Mode of Action	Bacteria Types	Antibiotic Groups	Resistance Mechanism	Worldwide Cost	References
Extended-spectrum beta-lactamase (ESBL)	Gram-negative bacteria, such as *E. coli*, *Klebsiella*, and Pseudomonas	Beta-lactams, such as penicillin and cephalosporin	Production of enzymes that hydrolyze beta-lactam antibiotics	The estimated cost of $55 billion annually by 2050 (O'Neill Report)	(Espinoza & Espinoza, 2020), (Algammal et al., 2020),

Mode of Action	Bacteria Types	Antibiotic Groups	Resistance Mechanism	Worldwide Cost	References
Methicillin-resistant Staphylococcus aureus (MRSA)	Gram-positive bacteria, such as S. aureus	Beta-lactams, such as penicillin and cephalosporins	Production of altered penicillin-binding proteins (PBPs) that have reduced affinity for beta-lactam antibiotics	The estimated cost of $3 billion annually in the United States alone (CDC)	(Serra-Burriel et al., 2020), (Palmeira & Ferreira, 2020).
Multi-drug resistance (MDR)	Various bacterial species, including Gram-positive and Gram-negative bacteria	Multiple antibiotic classes	Overexpression of efflux pumps, alterations in target sites, and other mechanisms	The estimated cost of $21-34 billion annually in the United States alone (CDC)	
Carbapenem-resistant Enterobacteriaceae (CRE)	Gram-negative bacteria, such as *Klebsiella* and *E. coli*	Carbapenems and other antibiotic classes	Production of carbapenemases, impermeability, overexpression of efflux pumps, alterations in target sites, and other mechanisms	The estimated cost of $2.9 billion annually in the United States alone (CDC)	

Examine the Impact of AMR on Human Health, Burden of Disease, Mortality Rates, and Healthcare Costs

The human health consequences of antimicrobial resistance (AMR) are substantial, including higher rates of sickness, mortality, and healthcare expenditures (Dunachie, Day, & Dolecek, 2020). Among the many negative effects of AMR on human health is an increasing disease burden. Longer hospital stays, more serious illnesses, and increased morbidity and mortality rates have all been linked to infections caused by AMR bacteria. Methicillin-resistant *Staphylococcus aureus* (MRSA) infections have a higher mortality rate than other types of bacterial infections. Infections caused by *carbapenem-resistant Enterobacteriaceae* (CRE) have been linked to higher fatality rates and longer hospital stays. AMR illnesses have a higher mortality rate than those caused by infections caused by bacteria that aren't resistant. Up to 50% of mortality has been linked to infections caused by *carbapenem-resistant Klebsiella pneumoniae* (CRKP). Due to the increased difficulty and expense of treating AMR infections, healthcare expenditures have increased. The cost of treating an infection caused by MRSA can be up to three times that of treating an infection caused by a non-resistant variant of the bacteria. As with non-resistant bacteria, the cost of treating a patient infected with a CRE strain can be up to three times greater. The consequences of AMR on human health are substantial and varied. It's a big issue for public health and calls for cooperation from government, medical professionals, and citizens. Appropriate antibiotic usage, infection prevention and control measures, and funding for antibiotic research and development are all examples of tactics that can be used to slow or stop the spread of AMR (MacKinnon et al., 2020; Dadgostar & Resistance, 2019; Limmathurotsakul et al., 2019).

Evaluate the Economic Costs of AMR, Costs of Treatment, Lost Productivity, and Increased Healthcare Expenditures

Antimicrobial resistance (AMR) not only has significant impacts on human health but also has economic costs associated with it (Zhen et al., 2021). There are some ways in which AMR affects the economy such as increased healthcare costs: AMR infections require more complex and expensive treatments, including longer hospital stays and the use of more expensive antibiotics. These increased healthcare costs can place a burden on individuals, healthcare systems, and governments. A study by the World Bank estimated that by 2050, the cumulative economic costs of AMR could reach $100 trillion globally. Lost productivity: AMR infections can result in longer hospital stays, extended sick leave, and even death, all of which can lead to lost productivity. This can have a significant impact on individuals, businesses, and the economy as a whole (Okunogbe et al., 2022). Impact on agriculture and food production: AMR in animals and crops can also have economic costs. For example, the use of antibiotics in agriculture can contribute to the development of AMR, which can reduce crop yields, increase animal mortality, and result in economic losses for farmers. **Impact on international trade:** AMR can also have an impact on international trade, as countries may impose restrictions on the import of goods from countries with high levels of AMR. This can have economic implications for countries that rely on international trade for economic growth. The economic costs of AMR are significant and can have wide-ranging impacts on individuals, healthcare systems, businesses, and the economy as a whole. Governments, healthcare providers, and other stakeholders ought to work together to address AMR by funding antibiotic research and development, bolstering infection prevention and control efforts, and encouraging more responsible antibiotic use (Paramasivam et al., 2023), (Wozniak, Barnsbee, Lee, Pacella, & Control, 2019;).

Assess the Effectiveness of Current Strategies for Addressing AMR, Antimicrobial Stewardship Programs and Infection Prevention and Control Measures

Antimicrobial resistance (AMR) is a complex problem that requires a multifaceted approach to address it effectively (Harun et al., 2022). Effective current approaches to antimicrobial resistance include: To slow the spread of antibiotic-resistant bacteria, many institutions have implemented antimicrobial stewardship programs (ASPs). Guidelines and protocols for antibiotic usage, monitoring and tracking antibiotic use and resistance, and teaching and training for healthcare personnel are typical components of such programs. There is evidence that ASPs can help curb the overuse of antibiotics, boost patient outcomes, and slow the spread of antimicrobial resistance. The primary goal of infection prevention and control strategies is to stop the spread of disease, including illnesses caused by bacteria resistant to antibiotics. Hygiene practices such as washing one's hands, disinfecting one's surroundings, wearing protective gear, and avoiding contact with others are all part of these protocols. Infection prevention and control techniques have been demonstrated to be useful in lowering the spread of bacteria resistant to antibiotics in healthcare facilities. New antibiotic development is necessary to combat the spread of antimicrobial resistance. However, there are many obstacles to developing new antibiotics, such as the high failure rate of antibiotic research programs and the lengthy and expensive nature of the process itself. While these approaches have shown promise in combating AMR, they are not without their share of difficulties in terms of both execution and long-term viability. For instance, healthcare providers may avoid adopting ASPs despite their potential benefits. Measures to prevent and control infections in healthcare facilities can be costly and difficult to adopt routinely. Many factors, including legislative constraints and financial incentives from the pharmaceutical sector, work against the development of new antibiotics. To effectively combat AMR, a collaborative effort by healthcare providers, governments, and other stakeholders is required. Antimicrobial stewardship programs and education and awareness campaigns are necessary, as are investments in the development of new antibiotics, the implementation of effective infection prevention and control measures, and the promotion of responsible antibiotic usage (Iwu & Patrick, 2021), (Villanueva et al., 2022), (Lacotte, Årdal, Ploy, & Control, 2020).

Table 4

Assessing the Impact and Economic Costs of Antimicrobial Resistance: Burden of Disease, Mortality Rates, Healthcare Costs, and Potential Interventions.

Impact of AMR	Description	Source
Burden of Disease	Antibiotic resistance in bacteria is a major problem since it can result in more people being sick, longer hospital stays, and greater overall healthcare expenses. Treatment failure and consequences may also become more likely.	(Chakrapani, Zare, & Ramakrishna, 2022), (Murray et al., 2022), (Wernli, Harbarth, Levrat, & Pittet, 2022), (El Omeiri et al., 2022).
Mortality Rates	There is an increase in mortality due to antibiotic resistance in microorganisms. The elderly, those with impaired immune systems, and those with preexisting diseases are particularly in danger.	
Healthcare Costs	Longer hospital stays, more frequent outpatient visits, and the use of more expensive medications are all associated	

Impact of AMR	Description	Source
	with antibiotic-resistant bacterial infections. An individual's or a country's healthcare costs may rise as a result of an increase in the usage of antibiotics and other hospital resources.	
Costs of Treatment	Due to the higher medical costs and longer hospital stays associated with treating antibiotic-resistant bacterial infections, they are more expensive to treat than their non-resistant counterparts.	
Lost Productivity	Prolonged illness and hospitalization from antibiotic-resistant bacterial infections can result in lost productivity and economic cost to individuals and society.	
Antimicrobial Stewardship Programs	The purpose of antimicrobial stewardship programs is to encourage prudent antibiotic usage and lessen the likelihood of antibiotic resistance. They can aid in enhancing patient care while decreasing overall healthcare expenditures.	
Infection Prevention and Control Measures	Antibiotic-resistant bacteria can be contained and the likelihood of infection is decreased by the use of infection prevention and control techniques such as hand washing, environmental cleaning, and patient isolation.	
Gaps in Knowledge	The mechanisms of resistance, the epidemiology of resistant bacteria, and the effect of AMR on population health and economic outcomes are only some of the areas where our knowledge is lacking.	
Potential Areas for Further Research	New medicines, improved diagnostics, and precision medicine for individualized treatment of bacterial infections could be the subject of future study.	
Effective Policies and Interventions	Policies and actions that are successful in reducing the negative effects of AMR on public health and the economy do so through raising public awareness, fostering education, funding research and development, and enacting all-encompassing plans of action.	

Conclusion

The development of resistance to antibiotics is a major public health problem that threatens international health safety. Antibiotic-resistant bacteria are a major threat because they can increase healthcare expenditures, lengthen the length of time patients spend in the hospital, and even cause death. The financial toll of AMR is high, and it's only going to climb in the years to come. To combat the spreading issue of AMR, the discovery of novel antibiotics is essential. New antibiotic development, however, is time-consuming, expensive, and fraught with difficulty. Incentives for pharmaceutical businesses, removal of regulatory hurdles, and increased investment in R&D all require a concerted effort on the part of all relevant parties. Infection prevention and control methods, proper use of antibiotics through antimicrobial stewardship programs, and educational and awareness initiatives are all necessary to halt the spread of antibiotic-resistant bacteria. While these approaches have shown promise in combating AMR, there are still hurdles that must be overcome before they can be fully implemented and maintained. In conclusion, combating AMR calls for an international coalition of healthcare professionals, government officials, and others to work together. The stakes are too high not to act, as ignoring this issue will have serious effects on people's health and the global economy.

Future Prospective of Antimicrobial Resistance

Future developments in analyzing infection patterns, pathogen resistance, and targeted bacterial processes will revolutionize the field of bacterial infection control. One of the most important advances is the creation of diagnostic technologies that can identify bacterial strains and their resistance profiles quickly and accurately. To personalize treatments, forecast susceptibility, and lessen the spread of antibiotic resistance, precision medicine will combine patient health records with genetic and microbiome data. Massive amounts of genomic and clinical data will be analyzed by big data analytics and AI algorithms to find trends, forecast epidemics, and locate novel therapeutic targets. To eradicate drug-resistant infections, scientists will employ gene-editing tools like CRISPR. Natural antimicrobial agents, bacteriophages, and immunotherapies, among others, will rise to prominence as promising new treatment options. To effectively monitor and manage bacterial infections, a One Health approach combining coordination between human health professionals, veterinarians, environmental scientists, and legislators is required. The prevention and treatment of bacterial infections, the lessening of antibiotic resistance, and the improvement of global health outcomes are all areas where these developments hold significant promise.

References

Acar, J., & Röstel, B. (2001). Antimicrobial resistance: an overview. *Revue scientifique et technique (International Office of Epizootics)*, *20*(3), 797–810. https://doi.org/10.20506/rst.20.3.1309

Ahmed, N., Tahir, K., Aslam, S., Cheema, S. M., Rabaan, A. A., Turkistani, S. A., Garout, M., Halwani, M. A., Aljeldah, M., Al Shammari, B. R., Sabour, A. A., Alshiekheid, M. A., Alshamrani, S. A., Azmi, R. A., Al-Absi, G. H., Zeb, S., & Yean, C. Y. (2022). Heavy Metal (Arsenic) Induced Antibiotic Resistance among Extended-Spectrum β-Lactamase (ESBL) Producing Bacteria of Nosocomial Origin. *Pharmaceuticals*, *15*(11), 1426. https://doi.org/10.3390/ph15111426

Algammal, A. M., Hetta, H. F., Elkelish, A., Alkhalifah, D. H. H., Hozzein, W. N., Batiha, G. E.-S., El Nahhas, N., & Mabrok, M. A. (2020). Methicillin-Resistant Staphylococcus aureus (MRSA): One Health Perspective Approach to the Bacterium Epidemiology, Virulence Factors, Antibiotic-Resistance, and Zoonotic Impact. *Infection and Drug Resistance*, *13*, 3255–3265. https://doi.org/10.2147/IDR.S272733

Andes, D., & Craig, W. A. (2005). Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. *Clinical Microbiology and Infection*, *11*, 10–17. https://doi.org/10.1111/j.1469-0691.2005.01265.x

Boyanova, L., Markovska, R., & Mitov, I. (2019). Multidrug resistance in anaerobes. *Future Microbiology*, *14*(12), 1055–1064. https://doi.org/10.2217/fmb-2019-0132

Chakrapani, G., Zare, M., & Ramakrishna, S. (2022). Current Trends and Definitions in High-performance Antimicrobial Strategies. *Current Opinion in Biomedical Engineering*, 100407. https://doi.org/10.1016/j.cobme.2022.100407

Coque, T. M., Baquero, F., & Cantón, R. (2008). Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. *Eurosurveillance*, *13*(47). https://doi.org/10.2807/ese.13.47.19044-en

Dadgostar, P. (2019). Antimicrobial Resistance: Implications and Costs. *Infection and Drug Resistance*, *12*(12), 3903–3910. https://doi.org/10.2147/idr.s234610

Dai, L., Sahin, O., Grover, M., & Zhang, Q. (2020). New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter. *Translational Research*, *223*, 76–88. https://doi.org/10.1016/j.trsl.2020.04.009

Dantas Palmeira, J., & Ferreira, H. M. N. (2020). Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in cattle production – a threat around the world. *Heliyon*, *6*(1), e03206. https://doi.org/10.1016/j.heliyon.2020.e03206

Ding, Y., Wang, Y., Hsia, Y., Sharland, M., & Heath, P. T. (2019). Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. *Annals of Clinical Microbiology and Antimicrobials*, *18*(1). https://doi.org/10.1186/s12941-019-0334-9

Dunachie, S. J., Day, N. P., & Dolecek, C. J. (2020). The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. *Current Opinion in Microbiology*, *57*, 95–101. https://doi.org/10.1016/j.mib.2020.09.013

Han, R., Shi, Q., Wu, S., Yin, D., Peng, M., Dong, D., Zheng, Y., Guo, Y., Zhang, R., & Hu, F. (2020). Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. *Frontiers in Cellular and Infection Microbiology*, *10*. https://doi.org/10.3389/fcimb.2020.00314

Harun, Md. G. D., Anwar, M. M. U., Sumon, S. A., Hassan, Md. Z., Mohona, T. M., Rahman, A., Abdullah, S. A. H. M., Islam, M. S., Kaydos-Daniels, S. C., & Styczynski, A. R. (2022). Rationale and guidance for strengthening infection prevention and control measures and antimicrobial stewardship programs in Bangladesh: a study protocol. *BMC Health Services Research*, *22*(1), 1–11. https://doi.org/10.1186/s12913-022-08603-0

Hofer, U. (2018). The cost of antimicrobial resistance. *Nature Reviews Microbiology*, *17*(1), 3–3. https://doi.org/10.1038/s41579-018-0125-x

Holmes, A. H., Moore, L. S. P., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., Guerin, P. J., & Piddock, L. J. V. (2016). Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet*, *387*(10014), 176–187. https://doi.org/10.1016/s0140-6736(15)00473-0

Iwu, C. D., & Patrick, S. M. (2021). An insight into the implementation of the global action plan on antimicrobial resistance in the WHO African region: A roadmap for action. *International Journal of Antimicrobial Agents*, *58*(4), 106411. https://doi.org/10.1016/j.ijantimicag.2021.106411

Johnson, N. L., Hayes, L. D., Brown, K., Hoo, E., & Ethier, K. A. (2014). *CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013. Morbidity and Mortality Weekly Report (MMWR), 63*(4), 3–27.

Jubair, N., Rajagopal, M., Chinnappan, S., Abdullah, N. B., & Fatima, A. (2021). Review on the Antibacterial Mechanism of Plant-Derived Compounds against Multidrug-Resistant Bacteria (MDR). *Evidence-Based Complementary and Alternative Medicine*, *2021*, 1–30. https://doi.org/10.1155/2021/3663315

Lacotte, Y., Årdal, C., & Ploy, M.-C. (2020). Infection prevention and control research priorities: what do we need to combat healthcare-associated infections and antimicrobial resistance? Results of a narrative literature review and survey analysis. *Antimicrobial Resistance & Infection Control*, *9*(1). https://doi.org/10.1186/s13756-020-00801-x

Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., Greko, C., So, A. D., Bigdeli, M., Tomson, G., Woodhouse, W., Ombaka, E., Peralta, A. Q., Qamar, F. N., Mir, F., & Kariuki, S. (2013). Antibiotic resistance—the need for global solutions. *The Lancet Infectious Diseases*, *13*(12), 1057–1098. https://doi.org/10.1016/s1473-3099(13)70318-9

Limmathurotsakul, D., Dunachie, S., Fukuda, K., Feasey, N. A., Okeke, I. N., Holmes, A. H., Moore, C. E., Dolecek, C., van Doorn, H. R., Shetty, N., Lopez, A. D., & Peacock, S. J. (2019). Improving the estimation of the global burden of antimicrobial resistant infections. *The Lancet Infectious Diseases*, *19*(11), e392–e398. https://doi.org/10.1016/s1473-3099(19)30276-2

MacKinnon, M. C., Sargeant, J. M., Pearl, D. L., Reid-Smith, R. J., Carson, C. A., Parmley, E. J., & McEwen, S. A. (2020). Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis. *Antimicrobial Resistance & Infection Control*, *9*(1), 1–22. https://doi.org/10.1186/s13756-020-00863-x

Mehdi, M. M., Abbas, A., Javed, S., Rehman, A., Ahmad, A., Abbas, M., ... & Zeb, S. (2023). The CRISPR-Cas System: How It Works In Bacteria And How It Can Be Used To Encounter Antimicrobial Resistant Pathogens. Journal of Pharmaceutical Negative Results, 14(3), 3681-3694. https://doi.org/10.47750/pnr.2023.14.03.461

Melzer, M., & Petersen, I. (2007). Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. *Journal of Infection*, *55*(3), 254–259. https://doi.org/10.1016/j.jinf.2007.04.007

Murray, C. J. (2022). Global Burden of Bacterial Antimicrobial Resistance in 2019: a Systematic Analysis. *The Lancet*, *399*(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

Okeke, I. N., Laxminarayan, R., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., Pablos-Mendez, A., & Klugman, K. P. (2005). Antimicrobial resistance in developing countries. Part I: recent trends and current status. *The Lancet. Infectious Diseases*, *5*(8), 481–493. https://doi.org/10.1016/S1473-3099(05)70189-4

Okunogbe, A., Nugent, R., Spencer, G., Powis, J., Ralston, J., & Wilding, J. (2022). Economic impacts of overweight and obesity: current and future estimates for 161 countries. *BMJ Global Health*, *7*(9), 481–493. https://doi.org/10.1136/bmjgh-2022-009773

Omeiri, N. E., Beith, A., Bruinsma, N., Caipo, M. L., Barcos, L. O., Mesplet, M., Barrio, L. D., Minassian, M., Arias, I. C., Vásquez, G. A. N., Corrales, M. L., & Ramon-Pardo, P. (2023). *Driving multisectoral antimicrobial resistance action in South America: Lessons learned from implementing an enhanced tripartite AMR country self-assessment tool. 16*, 100474–100474. https://doi.org/10.1016/j.onehlt.2022.100474

Organization, W. H. (2002). *The world health report 2002: reducing risks, promoting healthy life*. World Health Organization.

Organization, W. H. (2008). *World Health Report 2008 (The) Chinese*. World Health Organization.

Otsuka, Y. (2020). Potent Antibiotics Active against Multidrug-Resistant Gram-Negative Bacteria. *Chemical and Pharmaceutical Bulletin*, *68*(3), 182–190. https://doi.org/10.1248/cpb.c19-00842

Paramasivam, R., Gopal, D. R., Dhandapani, R., Subbarayalu, R., Elangovan, M. P., Prabhu, B., Veerappan, V., Nandheeswaran, A., Paramasivam, S., & Saravanan, M. (2023). Is AMR in Dairy Products a Threat to Human Health? An Updated Review on the Origin, Prevention, Treatment, and Economic Impacts of Subclinical Mastitis. *Infect Drug Resist*, *Volume 16*(6), 155–178. https://doi.org/10.2147/idr.s384776

Senok, A. C., Khanfar, H. S., Bindayna, K. M., & Botta, G. A. (2009). Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. *The Journal of Infection in Developing Countries*, *3*(04), 295–299. https://doi.org/10.3855/jidc.127

Serra-Burriel, M., Keys, M., Campillo-Artero, C., Agodi, A., Barchitta, M., Gikas, A., Palos, C., & López-Casasnovas, G. (2020). Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis. *PLoS ONE*, *15*(1). https://doi.org/10.1371/journal.pone.0227139

Shahzeb, K., & Iqra, R. (2019). Threats of bioterrorism in public health, Epidemiological clue, Detection and Safety pre-cautions for outbreaks. *Open Journal of Bacteriology*, *3*(1), 011–015. https://doi.org/10.17352/ojb.000011

Stefani, S., Chung, D. R., Lindsay, J. A., Friedrich, A. W., Kearns, A. M., Westh, H., & MacKenzie, F. M. (2012). Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. *International Journal of Antimicrobial Agents*, *39*(4), 273–282. https://doi.org/10.1016/j.ijantimicag.2011.09.030

Suay-García, B., & Pérez-Gracia, M. (2019). Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. *Antibiotics*, *8*(3), 122. https://doi.org/10.3390/antibiotics8030122

Swami, O. C. (2014). Strategies to Combat Antimicrobial Resistance. *JOURNAL of CLINICAL and DIAGNOSTIC RESEARCH*, *8*(7). https://doi.org/10.7860/jcdr/2014/8925.4529

Tacconelli, E., Sifakis, F., Harbarth, S., Schrijver, R., van Mourik, M., Voss, A., Sharland, M., Rajendran, N. B., Rodríguez-Baño, J., Bielicki, J., de Kraker, M., Gandra, S., Gastmeier, P., Gilchrist, K., Gikas, A., Gladstone, B. P., Goossens, H., Jafri, H., Kahlmeter, G., & Leus, F. (2018). Surveillance for control of antimicrobial resistance. *The Lancet Infectious Diseases*, *18*(3), e99–e106. https://doi.org/10.1016/S1473-3099(17)30485-1

Thanh Dong, L., V. Espinoza, H., & Luis Espinoza, J. (2020). Emerging superbugs: The threat of Carbapenem Resistant Enterobacteriaceae. *AIMS Microbiology*, *7*(3), 176–182. https://doi.org/10.3934/microbiol.2020012

Tilahun, M., kassa, Y., Gedefie, A., & Belete, M. A. (2021). Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review. *Infection and Drug Resistance*, *Volume 14*, 4363–4374. https://doi.org/10.2147/idr.s337611

Villanueva, P., Coffin, S. E., Mekasha, A., McMullan, B., Cotton, M. F., & Bryant, P. A. (2022). Comparison of Antimicrobial Stewardship and Infection Prevention and Control Activities and Resources between Low-/Middle- and High-income Countries. *Pediatric Infectious Disease Journal*, *41*(3S), S3–S9. https://doi.org/10.1097/inf.0000000000003318

Wernli, D., Harbarth, S., Levrat, N., & Pittet, D. (2022). A "whole of United Nations approach" to tackle antimicrobial resistance? A mapping of the mandate and activities of international organisations. *BMJ Global Health*, *7*(5), e008181. https://doi.org/10.1136/bmjgh-2021-008181

Wozniak, T. M., Barnsbee, L., Lee, X. J., & Pacella, R. E. (2019). Using the best available data to estimate the cost of antimicrobial resistance: a systematic review. *Antimicrobial Resistance & Infection Control*, *8*(1). https://doi.org/10.1186/s13756-019-0472-z

Yuan, B., Liu, J., Deng, Z., Wei, L., Li, W., Dou, Y., Chen, Z., Zhang, C., Xia, Y., Wang, J., Zhang, M., Yang, K., Ma, Y., & Kang, Z. (2021). A molecular architectural design that promises potent antimicrobial activity against multidrug-resistant pathogens. *NPG Asia Materials*, *13*(1). https://doi.org/10.1038/s41427-021-00287-y

Zeb, S., Mushtaq, M., Ahmad, M., Saleem, W., Rabaan, A. A., Naqvi, B. S. Z., Garout, M., Aljeldah, M., Al Shammari, B. R., Al Faraj, N. J., Al-Zaki, N. A., Al Marshood, M. J., Al Saffar, T. Y., Alsultan, K. A., Al-Ahmed, S. H., Alestad, J. H., Naveed, M., & Ahmed, N. (2022). Self-Medication as an Important Risk Factor for Antibiotic Resistance: A Multi-Institutional Survey among Students. *Antibiotics*, *11*(7), 842. https://doi.org/10.3390/antibiotics11070842

Zhen, X., Stålsby Lundborg, C., Sun, X., Zhu, N., Gu, S., & Dong, H. (2021). Economic burden of antibiotic resistance in China: a national level estimate for inpatients. *Antimicrobial Resistance & Infection Control*, *10*(1). https://doi.org/10.1186/s13756-020-00872-w